Bray Capital Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$850K Sell
4,786
-330
-6% -$60.7K 0.23% 83
2024
Q3
$1.01M Hold
5,116
0.25% 81
2024
Q2
$877K Hold
5,116
0.22% 83
2024
Q1
$932K Hold
5,116
0.24% 85
2023
Q4
$793K Hold
5,116
0.22% 89
2023
Q3
$763K Hold
5,116
0.23% 86
2023
Q2
$689K Hold
5,116
0.21% 92
2023
Q1
$815K Hold
5,116
0.24% 87
2022
Q4
$827K Hold
5,116
0.26% 88
2022
Q3
$687K Hold
5,116
0.22% 94
2022
Q2
$784K Hold
5,116
0.23% 93
2022
Q1
$829K Hold
5,116
0.21% 96
2021
Q4
$693K Hold
5,116
0.17% 99
2021
Q3
$552K Hold
5,116
0.14% 103
2021
Q2
$576K Sell
5,116
-102
-2% -$11.5K 0.15% 103
2021
Q1
$565K Hold
5,218
0.16% 101
2020
Q4
$559K Hold
5,218
0.16% 99
2020
Q3
$457K Hold
5,218
0.16% 99
2020
Q2
$512K Buy
5,218
+400
+8% +$35.2K 0.2% 93
2020
Q1
$367K Hold
4,818
0.17% 97
2019
Q4
$427K Sell
4,818
-350
-7% -$29.1K 0.15% 103
2019
Q3
$391K Hold
5,168
0.15% 103
2019
Q2
$376K Sell
5,168
-698
-12% -$54.9K 0.14% 109
2019
Q1
$473K Buy
5,866
+80
+1% +$6.54K 0.2% 95
2018
Q4
$533K Hold
5,786
0.27% 82
2018
Q3
$547K Hold
5,786
0.24% 83
2018
Q2
$536K Hold
5,786
0.25% 78
2018
Q1
$548K Buy
5,786
+149
+3% +$16.4K 0.26% 76
2017
Q4
$545K Sell
5,637
-322
-5% -$30.3K 0.26% 76
2017
Q3
$530K Sell
5,959
-145
-2% -$11K 0.28% 72
2017
Q2
$443K Sell
6,104
-4,000
-40% -$269K 0.24% 76
2017
Q1
$658K Sell
10,104
-22,144
-69% -$1.39M 0.37% 59
2016
Q4
$2.02M Sell
32,248
-365
-1% -$22.3K 1.21% 36
2016
Q3
$2.06M Buy
32,613
+307
+1% +$19.9K 1.24% 35
2016
Q2
$2M Buy
32,306
+1,980
+7% +$121K 1.24% 33
2016
Q1
$1.73M Sell
30,326
-2,052
-6% -$114K 1.5% 32
2015
Q4
$1.92M Sell
32,378
-5,990
-16% -$345K 1.22% 30
2015
Q3
$2.09M Sell
38,368
-467
-1% -$30.4K 1.33% 23
2015
Q2
$2.61M Sell
38,835
-660
-2% -$43.1K 1.5% 14
2015
Q1
$2.31M Buy
39,495
+15,095
+62% +$912K 1.37% 20
2014
Q4
$1.6M Buy
+24,400
New +$1.54M 1.04% 32

Other funds holding ABBV

Bray Capital Advisors's ABBV Position: Q4 2024 in Review

Bray Capital Advisors reduced its AbbVie (ABBV) stake by 6.5% in Q4 2024, selling an estimated $60.7K and leaving 4,786 shares worth $850K. The position accounts for 0.23% of the portfolio, ranked #83.

Bray Capital Advisors first reported a position in ABBV in Q4 2014 and has held it in 41 quarters since. The position peaked at $2.61M in Q2 2015. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Bray Capital Advisors held 4,786 shares of AbbVie worth $850K as of Q4 2024.
  • Bray Capital Advisors sold 330 AbbVie shares in Q4 2024, an estimated $60.7K.
  • AbbVie made up 0.23% of Bray Capital Advisors's portfolio in Q4 2024, its #83 holding.
  • Bray Capital Advisors first reported a position in AbbVie in Q4 2014 and has held it in 41 quarters since.
  • Bray Capital Advisors's AbbVie position peaked at $2.61M in Q2 2015.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.